长效皮下注射来那卡帕韦在多重耐药HIV-1经治患者中的疗效与安全性:2/3期试验第104周结果
这项正在进行的国际2/3期试验在42个中心纳入72例多重耐药HIV-1成人,口服来那卡帕韦负荷2周后每26周皮下注射来那卡帕韦联合研究者选择的优化背景方案。第104周时62%(44/71,95%CI 50;73)经FDA快照算法HIV-1 RNA<50拷贝/mL,排除缺失数据后为82%(44/54),耐受性良好。
要点
- 第104周62%(44/71,95%CI 50;73)经FDA快照算法HIV-1 RNA<50拷贝/mL。
- 排除缺失数据后82%(44/54)HIV-1 RNA<50拷贝/mL,CD4平均增加122 cells/µL(95%CI 80;165)。
- 14例出现来那卡帕韦治疗 emergent 耐药,其中7例维持用药下重新抑制;无4级或严重治疗相关不良事件。
核心结论
- 皮下注射来那卡帕韦联合优化背景方案耐受性良好,104周内病毒学抑制率高,为多重耐药HIV-1患者的重要治疗选择。
研究设计与样本
- 正在进行的国际2/3期试验,在42个中心纳入72例多重耐药HIV-1成人,口服来那卡帕韦负荷2周后每26周皮下注射联合研究者选择的优化背景方案,评估104周。
主要发现
- 第104周44/71例(62%,95%CI 50;73)经FDA快照算法HIV-1 RNA<50拷贝/mL;排除缺失数据后44/54例(82%)HIV-1 RNA<50拷贝/mL。
- 第104周CD4细胞计数平均增加122 cells/µL(95%CI 80;165),CD4<200 cells/µL比例从基线64%(46/72)降至29%(16/55)。
- 14例出现来那卡帕韦治疗 emergent 耐药,其中7例维持来那卡帕韦使用下重新抑制(HIV-1 RNA<50拷贝/mL)。
- 无4级或严重治疗相关不良事件;1例因注射部位反应停用研究药物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lenacapavir is a long-acting human immunodeficiency virus type 1 (HIV-1) capsid inhibitor for treatment of HIV-1 infection. We evaluated the efficacy and safety of lenacapavir in combination with an investigator-selected optimized background regimen (OBR) after 104 weeks in adults with multidrug-resistant HIV-1. METHODS: This ongoing, international, Phase 2/3 trial at 42 sites included 72 adults with multidrug-resistant HIV-1. Following a 2-week oral lenacapavir loading phase, participants received subcutaneous lenacapavir every 26 weeks with an OBR. HIV-1 RNA, CD4 cell counts, and adverse events were assessed over 104 weeks. One participant did not enter the extension phase. RESULTS: At Week 104, 44 of 71 participants (62%, 95% confidence interval [CI]: 50; 73) had HIV-1 RNA <50 copies/mL via US Food and Drug Administration (FDA) snapshot algorithm. When missing data (including discontinuations) were excluded, 44 of 54 participants (82%) had HIV-1 RNA <50 copies/mL at Week 104, mean CD4 cell count increased by 122 cells/µL (95% CI: 80; 165), and the proportion of participants with CD4 cell count <200 cells/µL decreased from 64% (46 of 72) at Baseline to 29% (16 of 55). Fourteen participants had treatment-emergent lenacapavir resistance; 7 resuppressed (HIV-1 RNA <50 copies/mL) while maintaining lenacapavir use. There were no Grade 4 or serious treatment-related adverse events. One participant discontinued study drug due to an injection site reaction. CONCLUSIONS: Treatment with subcutaneous lenacapavir in combination with an OBR was well tolerated and resulted in a high rate of virological suppression over 104 weeks. Lenacapavir represents an important treatment option in people with multidrug-resistant HIV-1.
引用
- Ogbuagu O, Molina JM, Chetchotisakd P, et al. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial. Clin Infect Dis. 2025. PMID: 39206943. doi:10.1093/cid/ciae423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。